News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 7, 2017Company files Patent to Increase Circulation around Stem Cell Implantation Sites to Improve Effects of Cellular Therapies
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced filing of a patent application covering synergy between intradiscal stem cell injection subsequent to stimulation of perispinal...
-
May 24, 2017Company Discovers Novel Method of Suppressing Inflammation Using Combination Autologous-Allogeneic System
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the "Company") announced today the filing of a patent application covering a novel means of suppressing inflammation associated with...
-
May 18, 2017Clinical Stage Stem Cell Company Continues Aggressive Pursuit of Personalized, Rapid to Implement, Autologous Regenerative Medicine Procedures
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today the acquisition of issued US patent #9,598,673 covering use of various stem cells for treatment of lower back pain through...
-
Apr 4, 2017Company Aims to Leverage Stem Cell Neuroregenerative Activity to Reduce Adverse Effects of Brain Radiation
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ), a clinical stage stem cell company, announced today filing of a patent application covering the use of its AmnioStem Universal Donor stem...
-
Mar 8, 2017Clinical Stage Stem Cell Company to Accelerate Product Development Leveraging Experience of Dr. Thomas Ichim
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today the appointment of Dr. Thomas Ichim to the position of Chief Scientific Officer. Dr. Ichim will lead development of the...
-
Feb 22, 2017Clinical Stage Stem Cell Company Expands Translational Research Activities with Acceptance into Premier San Diego Research Facility
Creative Medical Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion of its translational research program using its AmnioStem universal donor stem cell product through...
-
Dec 13, 2016Collaboration between Stem Cell Clinician, Neurologist, and Cell Therapy Developer Results in Novel Regenerative Approach to Stroke
Creative Medical Technology Holdings (the "Company") (OTCQB:CELZ) announced today filing of US patent application #62/400557 entitled "Treatment of Stroke by Amniotic Fluid Derived Stem Cell...
-
Dec 6, 2016Clinical Stage Stem Cell Therapeutics Company Aims to Develop "Universal Donor" Stem Cell "Drug" for Stroke Patients
Creative Medical Technology Holdings (OTCQB:CELZ) announced the appointment of Santosh Kesari, MD, PhD, FANA, FAAN to the Company's Scientific Advisory Board. Dr. Kesari will leverage his...
-
Nov 16, 2016Clinical Stage Stem Cell Therapeutics Company Expands Regenerative Medicine Portfolio to 'Off-the-Shelf' Allogeneic Stem Cell Products
Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of a wholly-owned subsidiary, AmnioStem LLC, focused on the development of therapeutic products derived from...
-
Nov 2, 2016Patent Rights Cover Multipotent Amniotic Fetal Stem Cells
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today signing of an exclusive license agreement with the University of California System to commercialize and develop a novel type...